BioSpace News Archive

Clover Biopharmaceuticals announced that it has successfully produced its trimeric Spike-protein subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies, provided financial results for its third fiscal quarter ended December 31, 2019.

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, introduces a novel method developed by researchers at Ben-Gurion University for screening and detecting new antibiotics.

Freudenberg Medical, a global developer and manufacturer of medical devices, components, and minimally invasive solutions, will be exhibiting at MD&M West alongside Freudenberg Medical companies VistaMed, Cambus Medical, Hemoteq, and Freudenberg Performance Materials.

Invacare Corporation announced its financial results for the fourth quarter and year ended December 31, 2019.

Edgewell Personal Care Company (NYSE: EPC) today announced results for its first fiscal quarter ending December 31, 2019.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Conference on Thursday, February 27, 2020 at 10:00 AM ET in New York, New York.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that, as anticipated, the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.

vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D).

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that a detailed examination of the Phase 3 TRILOGY 1 results for CaPre is underway, including specific clinical site audits and an audit of the central testing laboratory.